par Dubash, Taronish T.D.;Bardia, Aditya;Chirn, Brian;Reeves, Brittany B.A.;LiCausi, Joseph J.A.;Burr, Risa;Wittner, Ben;Rai, Sumit;Patel, Hitisha;Bihani, Teeru;Arlt, Heike;Bidard, François-Clément;Kaklamani, Virginia V.G.;Aftimos, Philippe ;Cortes, Javier;Scartoni, Simona;Fiascarelli, Alessio;Binaschi, Monica;Habboubi, Nassir;Iafrate, Anthony John;Toner, Mehmet;Haber, Daniel D.A.;Maheswaran, Shyamala
Référence Breast cancer research and treatment, 201, 1, page (43-56)
Publication Publié, 2023-08
Référence Breast cancer research and treatment, 201, 1, page (43-56)
Publication Publié, 2023-08
Article révisé par les pairs
Titre: |
|
Auteur: | Dubash, Taronish T.D.; Bardia, Aditya; Chirn, Brian; Reeves, Brittany B.A.; LiCausi, Joseph J.A.; Burr, Risa; Wittner, Ben; Rai, Sumit; Patel, Hitisha; Bihani, Teeru; Arlt, Heike; Bidard, François-Clément; Kaklamani, Virginia V.G.; Aftimos, Philippe; Cortes, Javier; Scartoni, Simona; Fiascarelli, Alessio; Binaschi, Monica; Habboubi, Nassir; Iafrate, Anthony John; Toner, Mehmet; Haber, Daniel D.A.; Maheswaran, Shyamala |
Informations sur la publication: | Breast cancer research and treatment, 201, 1, page (43-56) |
Statut de publication: | Publié, 2023-08 |
Sujet CREF: | Cancérologie |
Mots-clés: | Circulating tumor cells (CTCs) |
Elacestrant | |
ER + metastatic breast cancer | |
Fulvestrant resistance | |
Selective estrogen receptor degrader (SERD) | |
Note générale: | SCOPUS: ar.j |
Langue: | Anglais |
Identificateurs: | urn:issn:0167-6806 |
info:doi/10.1007/s10549-023-06998-w | |
info:scp/85162032401 | |
info:pmid/37318638 |